The global blood testing market size is calculated at USD 113.30 billion in 2025 and is forecasted to reach around USD 210.96 billion by 2034, accelerating at a CAGR of 7.16% from 2025 to 2034. The North America blood testing market size surpassed USD 46.49 billion in 2024 and is expanding at a CAGR of 7.28% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Blood Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Blood Testing Market, by Test Type
8.1.1. Glucose Testing
8.1.1.1. Market Revenue and Forecast
8.1.2. A1C Testing
8.1.2.1. Market Revenue and Forecast
8.1.3. Direct LDL Testing
8.1.3.1. Market Revenue and Forecast
8.1.4. Lipid Panel Testing
8.1.4.1. Market Revenue and Forecast
8.1.5. Prostate-specific Antigen Testing
8.1.5.1. Market Revenue and Forecast
8.1.6. COVID-19 Testing
8.1.6.1. Market Revenue and Forecast
8.1.7. BUN Testing
8.1.7.1. Market Revenue and Forecast
8.1.8. Vitamin D Testing
8.1.8.1. Market Revenue and Forecast
8.1.9. Thyroid-stimulating Hormone (TSH)
8.1.9.1. Market Revenue and Forecast
8.1.10. Serum Nicotine/Cotinine
8.1.10.1. Market Revenue and Forecast
8.1.11. High-sensitivity CRP Testing
8.1.11.1. Market Revenue and Forecast
8.1.12. Testosterone Testing
8.1.12.1. Market Revenue and Forecast
8.1.13. ALT Testing
8.1.13.1. Market Revenue and Forecast
8.1.14. Cortisol Testing
8.1.14.1. Market Revenue and Forecast
8.1.15. Creatinine Testing
8.1.15.1. Market Revenue and Forecast
8.1.16. AST Testing
8.1.16.1. Market Revenue and Forecast
8.1.17. Other Blood Tests
8.1.17.1. Market Revenue and Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Test Type
9.1.2. U.S.
9.1.2.1. Market Revenue and Forecast, by Test Type
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Test Type
9.2. Europe
9.2.1. Market Revenue and Forecast, by Test Type
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Test Type
9.2.3. Germany
9.2.3.1. Market Revenue and Forecast, by Test Type
9.2.4. France
9.2.4.1. Market Revenue and Forecast, by Test Type
9.2.5. Rest of Europe
9.2.5.1. Market Revenue and Forecast, by Test Type
9.3. APAC
9.3.1. Market Revenue and Forecast, by Test Type
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Test Type
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Test Type
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Test Type
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Test Type
9.4. MEA
9.4.1. Market Revenue and Forecast, by Test Type
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Test Type
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Test Type
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Test Type
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Test Type
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Test Type
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Test Type
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Test Type
10.1. Abbott
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. F. Hoffmann-La Roche AG
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Bio-Rad Laboratories, Inc.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. BioMerieux SA
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Quest Diagnostics
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Biomerica, Inc.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Becton, Dickinson and Company
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Siemens Healthineers
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Danaher Corporation
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Trinity Biotech Plc
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
12.1. About Us
12.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample